Cross-posted from The White House Briefing Room

FDA Emergency Use Authorization allows for alternative dosing regimen; increases JYNNEOS supply by up to five-fold

Combatting the monkeypox outbreak is a top priority of the Biden-Harris Administration. Today, as part of the Administration’s comprehensive effort to mitigate the spread of monkeypox, the Administration announced that it has taken action to increase the number of vaccine doses available by up to five times through an alternative dosing regimen. The Food and Drug Administration (FDA) today announced it is granting Emergency Use Authorization (EUA) for the JYNNEOS vaccine to be administered intradermally. Because intradermal administration requires a smaller dose, this change allows the number of available doses to increase by as much as five-fold while continuing to ensure the vaccine meets high standards for safety and quality.

The White House National Monkeypox Response team today outlined its plan to implement this approach and ensure providers and public health officials put the alternative dosing regimen into practice.

Read the White House fact sheet providing full details on these key actions and implementation plan.

Today’s announcement is part of the Biden-Harris Administration’s comprehensive strategy to combat the monkeypox outbreak and protect those at risk of contracting the virus. Since the first known cases in the United States, the Administration has developed a robust and agile strategy to expand and accelerate the production and distribution of vaccines, increased testing capacity from 6,000 tests per week to 80,000 tests per week, made treatments more accessible, and communicated on an ongoing basis with public health officials, state and local leaders, and individuals most impacted by the virus to date, including the LGBTQI+ community.